France-based Quantel Medical has obtained CE mark approval for the Vitra PDT photodynamic therapy laser platform to treat polypoidal choroidal vasculopathy (PCV) and central serous retinopathy (CSR).
The company intends to commercialize the laser platform immediately in countries requiring CE registration.
Quantel Medical CEO Jean-Marc Gendre said the company is currently the sole provider of a laser approved to treat these two very serious retinal conditions.
"This comes at an opportune moment, as demand for PDT treatment technologies is expected to increase as the disease’s true prevalence is realized," Gendre added.
"We’re confident that our world-class laser technology will provide ophthalmologists a quality, cost-effective solution, and are excited to begin commercialization in Europe and Asia."
PCV, a choroidal vasculature disease, can be seen in both men and women of many ethnicities. It is characterized by detachments of the pigmented epithelium and exudative changes, which can commonly lead to subretinal fibrosis.
CSR or central serous chorioretinopathy (CSC) is an eye disease, which induces visual impairment, and is characterized by leakage of fluid under the retina that has a propensity to accumulate under the central macula.
Quantel Medical, a division of Quantel, develops technologies to treat ocular diseases.